Neoadjuvant chemotherapy with carboplatin and paclitaxel in pregnant women with advanced stage cervical cancer: Maternal and perinatal outcomes

IF 1.7 4区医学 Q3 OBSTETRICS & GYNECOLOGY

Journal of gynecology obstetrics and human reproduction Pub Date : 2025-02-01 DOI:10.1016/j.jogoh.2024.102890

Bruna Elias Parreira Lopes Ferraz , Roney César Signorini Filho , Lucas Ribeiro Borges Carvalho , Michelle Samora Almeida , Tatiana Carvalho de Souza Bonetti , Edward Araujo Júnior , Antonio Braga , Sue Yazaki Sun

{"title":"Neoadjuvant chemotherapy with carboplatin and paclitaxel in pregnant women with advanced stage cervical cancer: Maternal and perinatal outcomes","authors":"Bruna Elias Parreira Lopes Ferraz , Roney César Signorini Filho , Lucas Ribeiro Borges Carvalho , Michelle Samora Almeida , Tatiana Carvalho de Souza Bonetti , Edward Araujo Júnior , Antonio Braga , Sue Yazaki Sun","doi":"10.1016/j.jogoh.2024.102890","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>Cervical cancer is the third most common cancer in Brazil. Although rare, its diagnosis during pregnancy represents a great challenge for the medical team and the patient. The objective of this study was to evaluate the maternal and perinatal outcomes of pregnant women who underwent neoadjuvant chemotherapy with carboplatin and paclitaxel for advanced stage cervical cancer.</div></div><div><h3>Methods</h3><div>This was a descriptive, retrospective study that included pregnant women with advanced stage cervical cancer (IB3 a IIIC1) who were treated at our center over 12 years. These patients received neoadjuvant chemotherapy with carboplatin plus paclitaxel during pregnancy to prevent disease progression.</div></div><div><h3>Results</h3><div>Tumor shrinkage of at least 50 % was observed in four patients, while the disease remained stable in three others. There was one case of fetal death without apparent cause at 29 weeks, but all other mothers were discharged from the hospital at the same time as their healthy newborns.</div></div><div><h3>Conclusion</h3><div>Chemotherapy with carboplatin and paclitaxel administered to pregnant women with advanced stage cervical cancer (IB3 - IIIC1) may have prevented disease progression without worsening neonatal outcomes.</div></div>","PeriodicalId":15871,"journal":{"name":"Journal of gynecology obstetrics and human reproduction","volume":"54 2","pages":"Article 102890"},"PeriodicalIF":1.7000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of gynecology obstetrics and human reproduction","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2468784724001697","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

Cervical cancer is the third most common cancer in Brazil. Although rare, its diagnosis during pregnancy represents a great challenge for the medical team and the patient. The objective of this study was to evaluate the maternal and perinatal outcomes of pregnant women who underwent neoadjuvant chemotherapy with carboplatin and paclitaxel for advanced stage cervical cancer.

Methods

This was a descriptive, retrospective study that included pregnant women with advanced stage cervical cancer (IB3 a IIIC1) who were treated at our center over 12 years. These patients received neoadjuvant chemotherapy with carboplatin plus paclitaxel during pregnancy to prevent disease progression.

Results

Tumor shrinkage of at least 50 % was observed in four patients, while the disease remained stable in three others. There was one case of fetal death without apparent cause at 29 weeks, but all other mothers were discharged from the hospital at the same time as their healthy newborns.

Conclusion

Chemotherapy with carboplatin and paclitaxel administered to pregnant women with advanced stage cervical cancer (IB3 - IIIC1) may have prevented disease progression without worsening neonatal outcomes.

查看原文本刊更多论文

卡铂和紫杉醇新辅助化疗在晚期宫颈癌孕妇中的应用：孕产妇和围产期结局

目的：宫颈癌是巴西第三大常见癌症。虽然罕见，但在怀孕期间的诊断对医疗团队和患者来说都是一个巨大的挑战。本研究的目的是评估接受卡铂和紫杉醇新辅助化疗治疗晚期宫颈癌的孕妇的孕产妇和围产期结局。方法：这是一项描述性、回顾性研究，纳入了在我们中心治疗超过12年的晚期宫颈癌（IB3 a IIIC1）孕妇。这些患者在怀孕期间接受卡铂加紫杉醇的新辅助化疗以预防疾病进展。结果：4例患者肿瘤缩小至少50%，3例患者病情保持稳定。有一例在29周时无明显原因的胎儿死亡，但所有其他母亲都与健康的新生儿同时出院。结论：卡铂和紫杉醇联合化疗对妊娠晚期宫颈癌（IB3 - IIIC1）患者可预防疾病进展，且不影响新生儿预后。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of gynecology obstetrics and human reproduction Medicine-Obstetrics and Gynecology

CiteScore

3.70

自引率

5.30%

发文量

210

审稿时长

31 days

期刊介绍： Formerly known as Journal de Gynécologie Obstétrique et Biologie de la Reproduction, Journal of Gynecology Obstetrics and Human Reproduction is the official Academic publication of the French College of Obstetricians and Gynecologists (Collège National des Gynécologues et Obstétriciens Français / CNGOF). J Gynecol Obstet Hum Reprod publishes monthly, in English, research papers and techniques in the fields of Gynecology, Obstetrics, Neonatology and Human Reproduction: (guest) editorials, original articles, reviews, updates, technical notes, case reports, letters to the editor and guidelines. Original works include clinical or laboratory investigations and clinical or equipment reports. Reviews include narrative reviews, systematic reviews and meta-analyses.